Press Releases April 7, 2026 08:00 PM

Vishay Intertechnology Announces 2026 Annual Meeting of Stockholders

Vishay Intertechnology Announces 2026 Virtual Annual Meeting of Stockholders

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
VSH

Vishay Intertechnology, Inc. announced its 2026 Annual Meeting of Stockholders will occur virtually on May 18, 2026, allowing stockholders to participate online. Proxy materials are available electronically and in paper format. The company highlights its broad semiconductor and passive component portfolio serving multiple technology sectors worldwide.

Vishay Intertechnology Announces 2026 Annual Meeting of Stockholders
VSH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The 2026 annual stockholders meeting will be held virtually to improve accessibility and convenience for investors.
  • Vishay Intertechnology is a leading manufacturer of discrete semiconductors and passive electronic components serving diverse markets including automotive, industrial, consumer, and aerospace.
  • Proxy statements and voting materials will be distributed to shareholders and available online, reflecting standard governance practices.

MALVERN, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH) announced today that its Annual Meeting of Stockholders will be held at 9:00 a.m., U.S. eastern time, on Monday, May 18, 2026.

Vishay has adopted a virtual annual meeting in 2026. The annual meeting will be accessible to stockholders via the Internet at www.virtualshareholdermeeting.com/VSH2026.

Stockholders will receive a paper or electronic copy of the Company’s proxy statement, annual report to stockholders, proxy card and related materials for the 2026 annual meeting. These materials are also available for viewing, free of charge, on the Internet at ir.vishay.com.

To participate in the virtual meeting, stockholders will need the control number included in their proxy card or on their voting instruction form. Those without a control number may attend as guests of the meeting, but they will not have the option to vote their shares or ask questions during the virtual event.

About Vishay

Vishay manufactures one of the world’s largest portfolios of discrete semiconductors and passive electronic components that are essential to innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and healthcare markets. Serving customers worldwide, Vishay is The DNA of tech.® Vishay Intertechnology, Inc. is a Fortune 1,000 Company listed on the NYSE (VSH). More on Vishay at www.vishay.com.

The DNA of tech® is a registered trademark of Vishay Intertechnology.

Contact:
Vishay Intertechnology, Inc.
Peter Henrici
Executive Vice President, Corporate Development
+1-610-644-1300


Risks

  • No new financial or strategic initiatives were disclosed, leaving uncertainty about future growth drivers which could impact investor sentiment.
  • The announcement is limited to corporate governance and does not address market conditions or supply chain challenges affecting the semiconductor industry.
  • As a manufacturer in multiple sectors, Vishay is exposed to cyclical demand fluctuations in automotive, industrial, and technology markets, potentially impacting performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026